Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03586570 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects
A Phase 1 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03586570 is a Phase 1 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT03586570, a Phase 1 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.
Interventions
- DRUG Placebo
- DRUG Aprocitentan 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2018-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03586570
The ClinicalTrials.gov registry entry for NCT03586570 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03586570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03586570 about?
NCT03586570 is a clinical study titled "A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects". The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian subjects.
What is the current status of trial NCT03586570?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-07-17. Estimated completion is 2018-09-10.
What interventions are being tested in trial NCT03586570?
The interventions under investigation include: Placebo (DRUG), Aprocitentan 25mg (DRUG).
Who is sponsoring clinical trial NCT03586570?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.